<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349531</url>
  </required_header>
  <id_info>
    <org_study_id>248.615</org_study_id>
    <nct_id>NCT00349531</nct_id>
  </id_info>
  <brief_title>A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS</brief_title>
  <official_title>A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the effects on RLS symptoms and sleep&#xD;
      disturbance of pramipexole (Mirapexin) 0.125 mg/day to 0.75 mg/day per os for 12 weeks,&#xD;
      compared to placebo, in the treatment of patients with idiopathic Restless Legs Syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: change from baseline after 12 weeks in IRLS total score. Co-primary endpoint: change from baseline after 12 weeks in MOS sleep disturbance score.</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints: CGI-I and IRLS responder rate other MOS dimensions, RLS-6 items 4-6, IRLS item 10, VAS ,Verbal Fluency Tests ,RLS-QoL scores PGI responder rate adverse event profile, systolic and diastolic blood pressure, pulse rate</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">369</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent consistent with ICH-GCP and local IRB/IEC requirements&#xD;
             obtained prior to any study procedures being performed and the ability and willingness&#xD;
             to comply with study treatment regimen and to attend study assessments.&#xD;
&#xD;
          2. Male or female out-patients aged 18-80 years.&#xD;
&#xD;
          3. Diagnosis of idiopathic RLS according to the clinical RLS criteria of the IRLSSG&#xD;
             [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS:&#xD;
&#xD;
               -  An urge to move the legs, usually accompanied or caused by uncomfortable and&#xD;
                  unpleasant sensations in the legs. (Sometimes the urge to move is present without&#xD;
                  the uncomfortable sensations and sometimes the arms or other body parts are&#xD;
                  involved in addition to the legs)&#xD;
&#xD;
               -  The urge to move or unpleasant sensations begin or worsen during periods of rest&#xD;
                  or inactivity such as lying or sitting&#xD;
&#xD;
               -  The urge to move or unpleasant sensations are partially or totally relieved by&#xD;
                  movement, such as walking or stretching, at least as long as the activity&#xD;
                  continues&#xD;
&#xD;
               -  The urge to move or unpleasant sensations are worse in the evening or night than&#xD;
                  during the day or only occur in the evening or night. (When symptoms are very&#xD;
                  severe, the worsening at night may not be noticeable but must have been&#xD;
                  previously present).&#xD;
&#xD;
          4. RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to&#xD;
             baseline (Visit 2).&#xD;
&#xD;
          5. IRLS total score &gt;15 at baseline (Visit 2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of child-bearing potential who do not use during the trial an adequate method of&#xD;
             contraception.&#xD;
&#xD;
          2. Women of child-bearing potential not having negative pregnancy test at screening.&#xD;
&#xD;
          3. Breastfeeding women.&#xD;
&#xD;
          4. Concomitant or previous pharmacologic therapy for RLS with: dopamine agonists or&#xD;
             levodopa (within 14 days prior to baseline), levodopa with augmentation, unsuccessful&#xD;
             prior treatment with non-ergot dopamine agonists.&#xD;
&#xD;
          5. All treatment less than 14 days or concomitant treatment with medication or dietary&#xD;
             supplements which could significantly influence RLS symptoms.&#xD;
&#xD;
          6. Withdrawal symptoms.&#xD;
&#xD;
          7. Pramipexole non-responders in other indications than RLS.&#xD;
&#xD;
          8. Patients with known hypersensitivity to pramipexole or any other component of the&#xD;
             investigational product or placebo tablets.&#xD;
&#xD;
          9. Diabetes mellitus requiring insulin therapy.&#xD;
&#xD;
         10. Any of the following laboratory results at screening:&#xD;
&#xD;
               -  any clinically significant abnormalities in laboratory parameters;&#xD;
&#xD;
               -  haemoglobin below LLN.&#xD;
&#xD;
         11. Clinically significant renal disease or calculated creatinine clearance lower than 30&#xD;
             mL/minute.&#xD;
&#xD;
         12. Clinically significant hepatic disease or GPT &gt;2 times the ULN.&#xD;
&#xD;
         13. Serum ferritin &lt;10 ng/mL.&#xD;
&#xD;
         14. History of/or malignant melanoma.&#xD;
&#xD;
         15. History of/or clinically significant vision abnormalities.&#xD;
&#xD;
         16. History of/or any other sleep disorder (other than RLS-related).&#xD;
&#xD;
         17. History of/or major depressive disorder or any psychotic disorder, mental disorders or&#xD;
             any present Axis I psychiatric disorder according to DSM IV requiring any medical&#xD;
             therapy.&#xD;
&#xD;
         18. History of/or clinical signs of suicidal behaviour, suicide ideation or acute suicidal&#xD;
             tendency according to the investigator's opinion.&#xD;
&#xD;
         19. History of/or alcohol abuse or drug addiction (within 2 years).&#xD;
&#xD;
         20. Patients on a shift-work-schedule or who are otherwise unable to follow a regular&#xD;
             sleep-wake cycle.&#xD;
&#xD;
         21. Participation in an investigational drug study within one month.&#xD;
&#xD;
         22. Any clinically significant conditions that would interfere or constitute a health&#xD;
             hazard for the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.615.45103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kgs. Lyngby</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.45102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København K</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.45101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.45104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaerløse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin-Steglitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Görlitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hattingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.49104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35302</name>
      <address>
        <city>BIrr</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carrigtwohill</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.35303</name>
      <address>
        <city>Castlecomer</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39007 Policlinico di Bari - Università di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39006 Ospedale Civile di Dolo</name>
      <address>
        <city>Dolo (VE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39002 Ospedale S. Martino - A. O. Università di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39008 Policlinico Gaetano Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39001 Istituto San Raffaele Turro</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39004 IRCCS Fondazione Istituto Neurologico &quot;C. Mondino&quot;</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39005 Ospedale S. Chiara</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.39003 A. O. Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fevik</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moelv</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.47105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tvedestrand</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3408 Hospital Nuestra Señora de Sonsoles</name>
      <address>
        <city>Avila</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3402</name>
      <address>
        <city>Maderid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3404 Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3406</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3407</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.3403 Hospital General de Catalunya</name>
      <address>
        <city>San Cugat del Valles (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hedemora</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.46104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.615.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Green, Crawley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.615_U07-2081.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.615_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>July 6, 2006</study_first_submitted>
  <study_first_submitted_qc>July 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2006</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

